David Hogg

David Hogg

Auto-generated profile, based on publicly available information

David Hogg

Princess Margaret Cancer Centre, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2015 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
DHDavid W. Hogg
David W. Hogg
MPMatthew E. Pamenter
Matthew E. Pamenter
DDDavid J. Dukoff
David J. Dukoff
LBLeslie T. Buck
Leslie T. Buck

7 February 2018 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
DHD. W. Hogg
D. W. Hogg
YCY. Chen
Y. Chen
ADA. L. D'AQuila
A. L. D'AQuila
MXM. Xu
M. Xu
MHM. Husić
M. Husić
DLD. A. Lovejoy
D. A. Lovejoy

1 August 2013 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
HKHatem Krema
Hatem Krema
LDLaura A. Dawson
Laura A. Dawson
DHDavid Hogg
David Hogg
NLNormand Laperriere
Normand Laperriere

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YKYada Kanjanapan
Yada Kanjanapan
DDDaphne Day
Daphne Day
LWLisa Wang
Lisa Wang
AHAaron R. Hansen
Aaron R. Hansen
ARAlbiruni Ryan Abdul Razak
Albiruni Ryan Abdul Razak
PBPhilippe L. Bedard
Philippe L. Bedard
3063Background: A subset of patients (pts) treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) compared with pre-treatment kinetics, known as hyperprogression. The aim of this study was to explore the relationship between HPD, treatment-related toxicity and clinical factors. Methods: Consecutive pts enrolled in early-phase trials involving checkpoint inhibitors and/or costimulatory molecules at Princess Margaret Cancer Centre between 8/2012 – 9/2016 with CT scans available for RECIST 1.1 assessment in the pre-IO treatment (reference, REF) and post-IO treatment (experimental, EXP) periods were reviewed. HPD was defined as RECIST progression at the first on-treatment scan and ≥2-fold increase in TGR between EXP and REF periods. Pts who had prior IO were excluded. Treatment-related toxicities requiring systemic corticosteroids, hormone replacement, IO delay or cessation were considered clinically significant adverse events (CSAEs). Results: 182/352 pts were eligible fo...

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKSeth Kibel
Seth Kibel
NKNathan Kuehne
Nathan Kuehne
MRMauricio Ribeiro
Mauricio Ribeiro
TMThiago Pimentel Muniz
Thiago Pimentel Muniz
PWPhilip Wong
Philip Wong
MBMarcus Butler
Marcus Butler
E21575 Background: Adjuvant systemic therapies (ST) for patients with resected stage III melanoma have improved relapse-free survival; however, the role of adjuvant radiotherapy (RT), previously the mainstay adjuvant treatment, is undefined in the modern ST era. Real-world data detailing clinical practice changes and its impact on outcomes are needed to help inform the choice of adjuvant therapy for patients with resected stage III melanoma. Methods: In this single-center retrospective study, patients from Princess Margaret Cancer Centre with resected stage III cutaneous melanoma treated between 2010 and 2019 and fitting the 2016 Cancer Care Ontario guidelines for adjuvant RT were included. Demographic, pathological, and clinical data were abstracted from electronic medical records. PFS was defined as the time from lymph node dissection to local-regional recurrence in the treated nodal basin or distant recurrence. OS was defined as time from lymph node dissection to death by any cause. The Log-rank method was applied to assess survival endpoints. A p-value < 0.05 was considered statistically significant. Results: From 4,959 records reviewed, 109 patients were identified. Median age at time of surgical resection was 59.4 years (23.6-89.8), and 74 (68%) were male. Type of adjuvant therapy and number of local-regional recurrences (LR) are expressed in the table. The median follow-up among those alive at last follow-up was 54.2 months (range 1.9-122). The proportion of patients receiving adjuvant RT was higher between 2010 and 2014 than it was between 2015 and 2019 (59% to 26%), whilst the proportion of those receiving adjuvant ST progressively grew (3% to 50%). LR > 90 days following lymph node dissection as the first site of relapse or synchronously with progression to metastatic disease was rare in patients treated with either adjuvant RT (6.8%) or adjuvant ST (14.3%, chi-square p = 0.33). Median progression free survival was 12.3 months in patients treated with adjuvant RT and 43.8 months in patients treated with adjuvant ST (p = 0.007). Overall survival was not significantly different (p = 0.08). Conclusions: The advent of ST has changed our institution’s clinical practice with ST replacing RT as the primary adjuvant treatment modality. Our data suggests that in the current adjuvant treatment landscape, omission of RT does not seem to increase rates of local-regional recurrences, and patients with resected stage III melanoma can be safely spared from adjuvant RT without detrimental effect on survival.

10 March 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RCRuiQui Chen
RuiQui Chen
ESElliot Charles Smith
Elliot Charles Smith
SCSze Wah Samuel Chan
Sze Wah Samuel Chan
KHKatrina Hueniken
Katrina Hueniken
MBM. Catherine Brown
M. Catherine Brown
LELawson Eng
Lawson Eng
85 Background: Prior clinical trials in melanoma have demonstrated higher rates of irAEs from combination ICI therapy compared to monotherapy. However, this has not been well studied in the real-world where patients often have greater co-morbidities and less organ reserve. We aim to compare irAEs hospitalizations for melanoma patients on combination vs monotherapy ICIs. Methods: We performed a single centre retrospective chart review (Princess Margaret Cancer Centre, Toronto, ON) for all melanoma patients receiving ICI as standard of care (2012-2017) admitted with irAEs. Data collected include demographics, investigations, management and outcomes of hospitalizations. Descriptive analyses were performed to characterize hospitalizations and compare between ICI combination vs monotherapy groups. Results: Among 381 melanoma patients identified on standard of care ICI, 41 (11%) were admitted for irAE. Among those admitted, 10% received monotherapy with nivolumab, 22% pembrolizumab, 39% ipilimumab and 29% combination ICI. Admission rates were higher among patients receiving combination ICI compared to monotherapy (20% vs 8% p = 0.003). Prevalence of the most common irAEs were similar between combination and monotherapy groups: colitis (58% vs 59%), pneumonitis (8% vs 14%) and hepatitis (8% vs 10%). Less than half received invasive diagnostic tests (i.e, endoscopy) (42% combination vs 35% monotherapy, p = 0.50) with 3 (60%) and 5 (50%) confirming irAEs, respectively. Rates of infliximab use were similar between the combination and monotherapy group (25% vs 21%, p = 0.70). Average length of stay was shorter for patients on combination ICI compared to monotherapy (5 days vs 15 days, p = 0.08). irAE readmission rates were similar between patients receiving combination ICI compared to monotherapy (20% vs 17%, p = 0.65). Conclusions: Despite higher admission rates among patients receiving combination ICI, there was a trend towards shorter hospitalizations. Other outcomes including diagnoses, investigations and management were not significantly different between patients receiving combination vs ICI monotherapy.